Abstract:The current review described a 55-year woman using 28 months to finish her surgery-based radiation-free multimodality treatment journey to fight International Federation of Gynaecology & Obstetrics (FIGO) 2018 clinical stage IIA2 (cT2aN0M0) squamous cell carcinoma (SCC) of the cervix. She received six cycles of perioperative adjuvant therapy, including three cycles of neoadjuvant therapy (NAT) and three cycles of postoperative adjuvant therapy by using combination of dose-dense chemotherapy (CT, weekly paclitaxel 80 mg/m2+triweekly cisplatin 40 mg/m2), immunotherapy (IO, triweekly pembrolizumab 200 mg) and half-dose anti-angiogenic agent (triweekly bevacizumab 7.5 mg/kg) plus interval radical surgery (radical hysterectomy + bilateral salpingo-oophorectomy + bilateral pelvic lymph node dissection + para-aortic lymph node sampling) and following maintenance therapy with monthly 22 cycles of half-dose of IO (pembrolizumab 100 mg) and concomitant 4 cycles of single-agent CT (paclitaxel 175 mg/m2) and 18 cycles of half-dose anti-angiogenic agent (bevacizumab 7.5 mg/kg). During the cervical SCC fighting journey, two unwanted adverse events (AEs) occurred. One was pseudo-progressive disease during the NAT treatment and pathology-confirmed upgrading FIGO stage IIIC1p (ypT2a1N1M0) after radical surgery and the other was the occurrence of hypothyroidism during the post operative adjuvant therapy. Based on this case we presented, we review the recent trend in the management of women with locally advanced cervical cancer (LACC) using the radiation-free but surgery-based multimodality strategy and highlight the strengths and limitations about perioperative adjuvant therapy with dose-dense CT + IO + half-dose anti-angiogenic agent and maintenance treatment of half-dose IO combining with short-term single agent CT and following long-term half-dose anti-angiogenic agent. All underscore the possibility that women with LACC have an opportunity to receive surgery-based RT-free multi-modality strategy to manage their diseases with satisfactory results. Additionally, the evolving role of IO plus CT with/without anti-angiogenic agent functioning as either primary treatment or adjuvant therapy for the treatment of advanced CC has been in process continuously. Moreover, the patient's positive response to IO, pembrolizumab as an example, both during the primary and maintenance therapy, highlights the importance of integrating IO into CT regimens for CC, especially in cases where conventional therapies, RT as an example, are insufficient or who do not want to receive RT-based treatment. The sustained disease-free status of the patient over several years reinforces the potential of IO to significantly increase long-term survival outcomes in CC patients, particularly for those with LACC.

Surgical Treatment Combined with Postoperative Adjuvant Chemotherapy Offer a Viable Option to the Cervical Cancer in Stage ⅠB～ⅡA with Moderate and High-risk Factor for Recurrence

Neoadjuvant chemotherapy combined with radical surgery for stage IB2/IIA2 cervical squamous cell carcinoma: a prospective, randomized controlled study of 35 patients

Can Laparoscopic Nerve-Sparing Ultra-Radical Hysterectomy Play a Role in Locally Advanced Cervical Cancer? A Single-Center Retrospective Study

Could Adjuvant Chemotherapy Improve Prognosis For Cervical Cancer Patients With Elevated Pretreatment Serum Squamous-Cell Carcinoma Antigen?

[Analysis of Prognostic Factors in Patients with Cervical Squamous Cell Carcinoma of Stage Ib and IIa].

Treatment Results of Adjuvant Chemotherapy after Radical Hysterectomy for Intermediate-Risk Stage IB-IIB Cervical Cancer

[Efficacy of Postoperative Simple Chemotherapy and Concurrent Chemoradiotherapy in FIGO Stage IB2-IIB Cervical Cancer].

Short-term efficacy and security of preoperative afterloading brachytherapy combinded concurrent chemotherapy for patients with FIGO stage ⅠB2 and Ⅱ A2 cervical cancer

Safety and Effectiveness of Neoadjuvant Immunotherapy Combined with Chemotherapy Followed by Surgical Resection in Patients with Stage I-IIIA Small-Cell Lung Cancer: a Retrospective Single-Arm Clinical Trial.

Prognostic significance of poorly differentiated histology and impact of adjuvant chemotherapy in early squamous cell carcinoma of cervix uteri

Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial

[Results of Different Postoperative Adjuvant Therapies for Stage Ib-IIa Cervical Carcinoma with Risk Factors].

Role Of Adjuvant Therapy After Radical Hysterectomy In Intermediate-Risk, Early-Stage Cervical Cancer

Concurrent Chemotherapy and Adjuvant Extended Field Irradiation after Radical Surgery for Cervical Cancer Patients with Lymph Node Metastases

[Multidisciplinary Therapy after Radical Surgery in Stage I B1-Ii B Cervical Cancer Patients with Positive Lymph Nodes].

Adjuvant chemotherapy, a valuable alternative option in selected patients with cervical cancer.

Can Surgery Boost the Survival Benefit of Chemoradiotherapy in T1b1-T2a1 Stage Cervical Cancer with Lymph Node Metastasis? A Population-Based Study

Prognostic Evaluation of Postoperative Adjuvant Therapy for Operable Cervical Cancer: 10 Years' Experience of National Cancer Center in China.

Adjuvant chemotherapy after radiotherapy or concurrent chemoradiotherapy for pelvic lymph node-positive patients with locally advanced cervical cancer: a propensity score matching analysis

Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer

The Long-Term Efficacy of Neoadjuvant Chemotherapy Followed by Radical Hysterectomy Compared with Radical Surgery Alone or Concurrent Chemoradiotherapy on Locally Advanced-Stage Cervical Cancer